Novo Nordisk chief calls for more risk-taking to counter weight-loss drug rivals

Novo Nordisk's leadership is advocating for a higher-risk strategy to spur new growth as competition intensifies in the weight-loss drug market. Chief Mike Doustdar emphasized the need to embrace potential failures to regain momentum after rivals began eroding the market share of its blockbuster drug, Ozempic. The Danish pharmaceutical giant was briefly Europe's most valuable company in 2023.